generation o: how did we get here? what can we do?

43
Genera&on O How did we get here? What can we do? Melanie Willows B.Sc. M.D. C.C.F.P. C.A.S.A.M. C.C.S.A.M. Clinical Director, Substance Use and Concurrent Disorders Program Mano&ck Public Informa&on Mee&ng On Fentanyl November 14, 2012

Upload: the-royal-mental-health-centre

Post on 13-May-2015

158 views

Category:

Health & Medicine


1 download

DESCRIPTION

Youth and Opioid Addictions: by Melanie Willows, Clinical Director, Substance Use and Concurrent Disorders Program at The Royal

TRANSCRIPT

Page 1: Generation O: How did we get here? What can we do?

Genera&on O How did we get here? What can we do? 

Melanie Willows B.Sc. M.D. C.C.F.P. C.A.S.A.M. C.C.S.A.M. 

Clinical Director, Substance Use and Concurrent Disorders Program 

Mano&ck Public Informa&on Mee&ng On Fentanyl November 14, 2012 

Page 2: Generation O: How did we get here? What can we do?

Discussion Points 

•  Current paOerns of substance use in youth •  What is an addic&on and what is experimental •  Risk Factors and Protec&ve Factors for Addic&on •  What is an opioid?  Why are opioids so addic&ve? 

Page 3: Generation O: How did we get here? What can we do?

Discussion Points cont’d 

•  What makes fentanyl so dangerous? 

•  Signs and symptoms of opioid intoxica&on and withdrawal 

•  Preven&on and Treatment of opioid addic&on  in youth 

Page 4: Generation O: How did we get here? What can we do?

A Genera&on Exposed… 

•  Although experimenta&on with alcohol and other drugs is a natural part of adolescence, experimenta&on involving opioids is high risk as addic&on occurs much more rapidly than with other drugs     

»  Na&onal Ins&tute of Drug Addic&on (NIDA) 

Page 5: Generation O: How did we get here? What can we do?

Table 1. Past Year Drug Use (%) for the Total Sample, and by Sex and Grade, 2011 OSDUHS (CAMH)  

Total  Male  Female  G7  G8  G9  G10  G11  G12 

Alcohol  54.9  54.6  55.1  17.4  26.4  50.5  59.6  75.5  78.4 

Cannabis  22.0  23.0  21.0  2.4  5.9  11.9  23.5  36.8  36.4 

Binge Drinking 

22.3  22.7  21.8  1.1  4.1  13.7  24.4  35.3  39.7 

Opioid Pain Relievers (NM) 

14.0  12.9  15.2  8.5  10.9  13.0  14.9  18.0  16.0 

CigareOes  8.7  9.3  8.2  2.8  3.7  10.3  14.5  14.4 

Page 6: Generation O: How did we get here? What can we do?

What is Addic&on? 

•  Chronic disease of brain reward circuitry •  Addic&on is characterized by inability to consistently abstain, impairment in behavioural control, craving, diminished recogniMon of significant problems with one’s behaviours and interpersonal relaMonships, and a dysfuncMonal emoMonal response.     

»  Excerpt from American Society of Addic&on Medicine (ASAM) defini&on 

Page 7: Generation O: How did we get here? What can we do?

Risk Factors for Addic&on •  Environment 

–  culture and society  (e.g., laws and availability of substances) 

–  peers and family including actudes   

–  early/persistent behavioural problems 

–  poor school performance, rebelliousness  

–  early onset of substance use 

•  Drug –  cost –  availability –  rapidity with which the agent 

reaches the brain  –  efficacy of the agent as a tranquilizer 

•  Host  –  inherited suscep&bility  –  psychophysiologic vulnerability 

to the effects of substances –  mental health disorders 

Page 8: Generation O: How did we get here? What can we do?

Protec&ve Factors 

•  Posi&ve temperament/self‐acceptance •  Intellectual ability/academic performance 

•  Suppor&ve family/home environment 

•  Caring rela&onship with at least one adult •  External support system (e.g. Religion/church) that encourages prosocial values  

•  Law abidance/avoidance of delinquent peer friendships 

Page 9: Generation O: How did we get here? What can we do?

What is an Opioid? 

•  Opioids belong to the drug classifica&on depressants (as do alcohol and benzodiazepines) 

•  Opioids are referred to as narco&cs (sleep inducing)  •  Opioids are effec&ve pain killers 

Page 10: Generation O: How did we get here? What can we do?

Common Abused Prescrip&on Opioids Drug Name  AcMve Ingredients 

Tylenol #1,2, 3  Codeine with acetaminophen 

M‐Eslon, MS Con&n  Morphine 

Percocet  Oxycodone with acetaminophen 

OxyNeo, Oxycon&n  Oxycodone 

Dilaudid  Hydromorphone 

Duragesic patch  Fentanyl 

Page 11: Generation O: How did we get here? What can we do?

Why Opioids?  Why now? 

•  Increasing availability of prescrip&on opioids –  1977   Oxycodone/Acetaminophen (Percocet) –  1989   Hydromorphone Hydrochloride (Dilaudid)  

–  1991   Morphine (MS IR) 

–  1992   Duragesic patch (fentanyl) –  1993   Morphine (MS Con&n)  

–  1996   Oxycodone Hydrochloride CR (Oxycon&n) –  1996   Duragesic patch added to Ontario Drug Benefits Formulary 

Page 12: Generation O: How did we get here? What can we do?

Why Opioids?  Why now? cont’d 

–  2000   Oxycodone IR (Oxycon&n IR) –  2000   Oxycodone Hydrochloride CR (OxyconMn) added to                 

    Ontario Drug Benefits Formulary 

–  2001   Hydromorphone Hydrochloride (Hydromorph Con&n CR) 

–  2002   Hydromorphone Hydrochloride (Hydromorph IR) –  2006   RanFentanyl Patch (generic) added to Ontario Drug  

            Benefits Formulary 

Page 13: Generation O: How did we get here? What can we do?

Fentanyl 

•  First synthesized by Paul Jannsen in 1959 •  Synthe&c potent opioid, rapid onset,  short dura&on of ac&on 

•  Said to be 80 to 100 &mes more potent  than morphine 

•  1960’s introduced as an intravenous  anesthe&c Sublimaze 

Page 14: Generation O: How did we get here? What can we do?

Fentanyl cont’d 

•  Illicit use of pharmaceu&cal fentanyl first appeared in the mid‐1970s in the medical community 

•  First Durogesic patch was approved by the US FDA in 1990, marketed in Canada in 1992 

•  Effec&ve pain medica&on for chronic moderate to severe pain when used properly 

Page 15: Generation O: How did we get here? What can we do?

Fentanyl cont’d 

•  Possible to interfere with transdermal delivery system thereby delivering larger doses of drug more rapidly to the brain (increases addic&ve poten&al of this drug) 

•  Difficult for user to determine dose (overdose risk) 

•  Depending on dose and delivery, physical withdrawal symptoms may be felt aler several days or weeks of fentanyl use 

Page 16: Generation O: How did we get here? What can we do?

Why Prescrip&on Opioids? Why Now?  Why Fentanyl?  

•  Perceived safety because it is a pharmaceu&cal 

•  More socially acceptable than heroin •  Purity •  Potent opioid (euphoria effects) 

Page 17: Generation O: How did we get here? What can we do?

Why Prescrip&on Opioids? Why Now?  Why Fentanyl? cont’d 

•  Easy access (inadequate monitoring of  prescrip&on narco&cs) 

•  High dose •  Possible to circumvent delivery system:  chew, suck, snort, smoke, inject 

Page 18: Generation O: How did we get here? What can we do?

Opioids Intoxica&on:  What do others observe? 

•  Drowsiness or “the Nod” •  Constricted or pinpoint pupils  •  Slurred speech  •  Impairment in aOen&on  or memory 

Page 19: Generation O: How did we get here? What can we do?

Risks of Opioid Intoxica&on 

•  Overdose (especially if new user, unknown dose, or combined with alcohol and/or benzodiazepines) 

•  Tolerance for euphoria increases more rapidly than tolerance to respiratory depression  

•  High risk for overdose if relapses aler a period of abs&nence 

•  Accidents •  Addic&on 

Page 20: Generation O: How did we get here? What can we do?

Opioids Withdrawal:  What can you observe? 

•  Dilated pupils •  Anxiety, irritability, anger (drug craving) •  Agita&on (cannot sit s&ll) •  Appears to be ill: nausea, vomi&ng, 

    diarrhea, sweats and chills, watery eyes, runny nose •  Yawning and Insomnia 

Page 21: Generation O: How did we get here? What can we do?

Preven&on of Opioid Dependence 

•  Delaying onset of all substance use •  Treatment of any underlying mental health issues •  Protec&ve factors previously discussed •  Safe and secure dispensing, storage and disposal measures of opioids must be reinforced for pa&ents, pharmacists and physicians. 

Page 22: Generation O: How did we get here? What can we do?

Treatment Op&ons 

•  Abs&nence following withdrawal management:  stop using opioids completely 

•  Opioid subs&tu&on therapy: receive daily dose  of long‐ac&ng approved and controlled opioid  such as methadone or Suboxone  (buprenorphine/naloxone) 

Page 23: Generation O: How did we get here? What can we do?

Op&ons for Treatment of  Opioid Dependence 

•  Abs&nence Based –  Pa&ent preference –  Has not tried abs&nence based –  Prior sustained response to abs&nence based treatment 

–  Are a younger age –  Are dependent only on opioids and in par&cular oral opioids 

Page 24: Generation O: How did we get here? What can we do?

Op&ons for Treatment of  Opioid Dependence cont’d 

•  Abs&nence Based –  Good prognos&c factors  

•  Socially stable •  Suppor&ve social network •  Short dura&on of addic&on •  No major psychiatric comorbidity 

Methadone Maintenance Treatment Program Standards and Clinical Guidelines 4th Edi&on February 2011 Buprenorphine/Naloxone for Opioid Dependence: Clinical Prac&ce Guideline CAMH 2011 

Page 25: Generation O: How did we get here? What can we do?

Non‐Opioid Management of  Opioid Withdrawal 

•  Clonidine ini&a&ng at 0.05mg TID, check BP if  less than 90/60 then hold; dosing of up to 0.1mg‐0.2mg po TID‐QID 

•  An&diarrheals :loperamide(Immodium) •  An&nauseants : dimenhydrinate (Gravol) 

Page 26: Generation O: How did we get here? What can we do?

Non‐Opioid Management of  Opioid Withdrawal cont’d 

•  Analgesics for myalgias: ibuprofen 

•  Night‐&me seda&on: Trazodone, Seroquel, or Benzodiazepine (but only for short term) 

Page 27: Generation O: How did we get here? What can we do?

Residen&al Withdrawal  Management Centre ‐ Level 2 

•  Supervision by trained but non‐medical staff 

•  May bring prescribed medica&ons •  Loca&ons 

–  OOawa     613.241.1525 

–  Cornwall   613.938.8506 –  Kingston   613.549.6461 or toll free 1.888.795.6688 

Page 28: Generation O: How did we get here? What can we do?

Substance Use and Concurrent Disorders Program Assessment and Stabiliza&on Unit  

•  Within SUCD program have one of three residen&al withdrawal management level 3 centres according  to CONNEX 

•  24/7 medical/psychiatric monitored detoxifica&on •  ASU ROMHC 12 beds  (CAMH 18 beds, Humber Regional Hospital 4 beds) TOTAL 34 BEDS  FOR ALL OF ONTARIO 

Page 29: Generation O: How did we get here? What can we do?

Substance Use and Concurrent Disorders Program Assessment and Stabiliza&on Unit  

•  Medical detoxifica&on with 

– Buprenorphine/Naloxone – Methadone – Clonidine, Diazepam 

•  Detoxifica&on followed by 28 day residen&al  treatment program 

Page 30: Generation O: How did we get here? What can we do?

Opioid Subs&tu&on Therapy for  Opioid Dependency 

•  Long‐ac&ng medica&ons can be used for detoxifica&on (inpa&ent or outpa&ent) or for maintenance – Methadone –  Buprenorphine/Naloxone (Suboxone) 

Page 31: Generation O: How did we get here? What can we do?

Methadone 

•  Synthe&c opioid that relieves drug cravings and withdrawal symptoms for 24 hr without inducing seda&on or euphoria 

•  Methadone has been extensively researched for safety and its effec&veness to  reduce morbidity and mortality in  intravenous heroin users. 

Page 32: Generation O: How did we get here? What can we do?

Methadone cont’d 

•  Regulated, physician requires a  methadone exemp&on 

•  Requirements of observed dosing, limits on ini&al dosing, weekly urine screens 

Page 33: Generation O: How did we get here? What can we do?

Youth and Methadone 

•  Pa&ents under 18 years of age may be considered for MMT, however abs&nence based treatment and/or opioid subs&tu&on tapering should also be considered for adolescents, par&cularly those with a shorter dura&on of opioid dependence 

Page 34: Generation O: How did we get here? What can we do?

Youth and Methadone cont’d 

•  The MMT physician should ensure that there has been a discussion with the adolescent (and other family members where possible) about poten&al issues with methadone including side effects, risks and difficulty of tapering off. 

Methadone Maintenance Treatment Program Standards and Clinical Guidelines 4th Edi&on February 2011 

Page 35: Generation O: How did we get here? What can we do?

Availability of Methadone  Maintenance Services 

•  Ontario currently has 37 000 people receiving methadone 

•  Several days to 2 week wait to be ini&ated onto methadone currently in OOawa  

•  Covered by for those with Ontario Drug Benefits or a private drug plan, otherwise cost is $6 per day 

Page 36: Generation O: How did we get here? What can we do?

Buprenorphine/Naloxone 

•  Is a par&al opioid agonist •  Approved in Canada in November 2007 •  Tablet taken sublingually under supervision at a pharmacy for at least the first 2 months 

Page 37: Generation O: How did we get here? What can we do?

Buprenorphine/Naloxone cont’d 

•  More rapid &tra&on to stabiliza&on than methadone 

•  May be easier to taper off this medica&on  than methadone 

•  Risk of precipitated withdrawal if taken  when not in significant withdrawal 

Page 38: Generation O: How did we get here? What can we do?

Other Treatment Resources for Youth 

•  Rideauwood •  Dave Smith Youth Treatment Centre  (residen&al treatment program ages 13‐21) 

•  Connex Ontario Health Services Informa&on •  Youth Services Bureau 

Page 39: Generation O: How did we get here? What can we do?

Treatment Outcomes for Youth 

•  High rate of treatment dropout is greater than  that seen in adults and is likely related to the adolescents’ typically low mo&va&on for treatment and the absence of perceiving their substance use  as a problem 

•  Adolescents most commonly report a social  situa&on or peer influence such as socializing with pretreatment friends as the context for ini&al relapse 

Page 40: Generation O: How did we get here? What can we do?

Post‐treatment factors 

•  Par&cipa&on in alercare treatment 

•  Peer/parental social support •  Prosocial ac&vi&es •  Post‐treatment factors have been found to be the most important determinant of clinical outcomes 

Page 41: Generation O: How did we get here? What can we do?

References 

•  Methadone Maintenance Treatment Program Standards and Clinical Guidelines, 4th edi&on February 2011 CPSO 

•  Buprenorphine/Naloxone for Opioid Dependence: Clinical Prac&ce Guideline 2011 (CAMH) 

•  Paglia‐Boak, A, Mann, RE, Adlaf, EM (2011). Drug use among Ontario students,1977‐2011: OSDUHS highlights. (CAMH Research Document Series No. 32). Toronto, ON: Centre for Addic&on and Mental Health. 

•  NIDA Na&onal Ins&tute on Drug Abuse 

Page 42: Generation O: How did we get here? What can we do?

References 

•  Lowinson & Ruiz’s Substance Abuse: A Comprehensive Textbook Filh Edi&on Chapter 57 Adolescent Substance Abuse R. Milin and S. Walker. Editors Pedro Ruiz &Eric Strain. LippincoO Williams & Wilkins, Philadelphia, PA, 2011 

•  Substance Abuse: A Comprehensive Textbook 4th Ed.  Lewinson et al. 2005 

•  Principles of Addic&on Medicine 4th ed.,  American Society of Addic&on Medicine. 2009 

Page 43: Generation O: How did we get here? What can we do?

Websites 

•  www.theroyal.ca •  www.connexontario.ca •  www.davesmithcentre.org •  www.rideauwood.org •  www.cahm.net •  www.asam.org •  www.nida.nhi.gov